Neutrophil activation in juvenile dermatomyositis: associations with muscle function and disease progression
Authors' conclusion
These findings highlight calprotectin and MPO-DNA as potential biomarkers for JDM muscle inflammation and functional outcomes.
Study context
- Population
- Children with juvenile dermatomyositis (JDM), juvenile idiopathic arthritis (JIA) and healthy controls
- Participants
- 36 / 13 / 21
- Exposure
- JDM vs JIA vs healthy controls
- JDMn = 36
- JIAn = 13
- Healthy controls (HCs)n = 21reference
- Outcome
- Plasma calprotectin (S100A8/A9) and MPO-DNA complexes (ELISA) as biomarkers for muscle inflammation and predictors of muscle outcomes
Methodological detailsbiomarker study, exploratory ROC analysis
- Biomarker study
- Exploratory ROC analysis
Main finding
As reported in the abstract
- JDM vs HCs: P = 0.0008
- JDM vs HCs: P = 0.0048
Observational data: associations, not effects.
Further findings
Correlation of calprotectin with muscle function scores (JDM)
- Childhood Myositis Assessment Scale (CMAS) r=−0.682, p = 0.0002
- MMT8 r=−0.59, p = 0.005
- Physician Global Assessment (PGA) muscle scores r = 0.452, p = 0.014
Elevated calprotectin and MPO-DNA together
- Tended to have greater disease activity and muscle involvement
Exploratory ROC analysis
- Baseline calprotectin and MPO-DNA may help distinguish active disease
- Exploratory
Baseline marker levels vs MMT8 improvement over time
- Calprotectin r = 0.634, p = 0.027
- MPO-DNA r = 0.582, p = 0.047
Original publication
Neutrophil activation in juvenile dermatomyositis: associations with muscle function and disease progression. Pediatr Rheumatol Online J. Published 10 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →